Endocrine Abstracts

Background: Since the FDA-approval of Lu177-DOTATATE and I131-MIBG radiopharmaceutical therapies in 2018, there is emerging real-world experience with their use. Only a few institutions in the US have both therapies available. Here, we describe our experience with these agents for patients with pheochromocytoma and paraganglioma (PPGL).Methods: This is a retrospective evaluation of all patients with progressive, metastatic, PPGL referred for radiopharmac...

Background: Renal neuroendocrine tumors (NETs) are a particularly rare subset of NETs, with fewer than 100 cases described in the literature. Of these, next generation sequencing (NGS) findings have been described in fewer than 10 cases, all but one of which had grade 1 disease.Methods: A single-center, IRB-approved retrospective analysis of patients with grade 2 or 3 well-differentiated renal NETs treated at our institution from 2016-2023 for whom NGS d...